This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2013 May 1;6(3):360-6.

doi: 10.1161/CIRCOUTCOMES.111.000014. Epub 2013 May 14.

Journey through cholesteryl ester transfer protein inhibition: from bench to bedside

Ioannis Karalis¹, Patrick C N Rensen, J Wouter Jukema

Affiliations

PMID: 23674310
DOI: 10.1161/CIRCOUTCOMES.111.000014

Review

Journey through cholesteryl ester transfer protein inhibition: from bench to bedside

Ioannis Karalis et al. Circ Cardiovasc Qual Outcomes. 2013.

. 2013 May 1;6(3):360-6.

doi: 10.1161/CIRCOUTCOMES.111.000014. Epub 2013 May 14.

Authors

Ioannis Karalis¹, Patrick C N Rensen, J Wouter Jukema

Affiliation

¹ Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

PMID: 23674310
DOI: 10.1161/CIRCOUTCOMES.111.000014

No abstract available

Keywords: atherosclerosis; high-density lipoprotein; lipids and lipoprotein metabolism.

PubMed Disclaimer

Similar articles

CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
Nicholls SJ. Nicholls SJ. Clin Pharmacol Ther. 2018 Aug;104(2):297-300. doi: 10.1002/cpt.1118. Epub 2018 Jun 27. Clin Pharmacol Ther. 2018. PMID: 29901215 Review.
Novel HDL-based therapeutic agents.
Joy TR. Joy TR. Pharmacol Ther. 2012 Jul;135(1):18-30. doi: 10.1016/j.pharmthera.2012.03.004. Epub 2012 Mar 23. Pharmacol Ther. 2012. PMID: 22465158 Review.
Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E. Laforest L, et al. Arch Cardiovasc Dis. 2009 Jan;102(1):43-50. doi: 10.1016/j.acvd.2008.06.021. Epub 2009 Jan 25. Arch Cardiovasc Dis. 2009. PMID: 19233108
Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
Stock J. Stock J. Atherosclerosis. 2013 Jun;228(2):329-31. doi: 10.1016/j.atherosclerosis.2013.03.011. Epub 2013 Mar 22. Atherosclerosis. 2013. PMID: 23623013 No abstract available.
Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Briand F, Thieblemont Q, Muzotte E, Sulpice T. Briand F, et al. Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):13-23. doi: 10.1161/ATVBAHA.112.252932. Epub 2012 Nov 8. Arterioscler Thromb Vasc Biol. 2013. PMID: 23139291

See all similar articles

Cited by

Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
Subedi BH, Joshi PH, Jones SR, Martin SS, Blaha MJ, Michos ED. Subedi BH, et al. Vasc Health Risk Manag. 2014 Apr 8;10:205-16. doi: 10.2147/VHRM.S45648. eCollection 2014. Vasc Health Risk Manag. 2014. PMID: 24748800 Free PMC article. Review.
Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
van der Tuin SJ, Kühnast S, Berbée JF, Verschuren L, Pieterman EJ, Havekes LM, van der Hoorn JW, Rensen PC, Jukema JW, Princen HM, Willems van Dijk K, Wang Y. van der Tuin SJ, et al. J Lipid Res. 2015 Nov;56(11):2085-93. doi: 10.1194/jlr.M057794. Epub 2015 Sep 4. J Lipid Res. 2015. PMID: 26342106 Free PMC article.
HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
Karalis I, Jukema JW. Karalis I, et al. Curr Cardiol Rep. 2018 Jun 21;20(8):66. doi: 10.1007/s11886-018-1004-9. Curr Cardiol Rep. 2018. PMID: 29926215 Free PMC article. Review.
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Kühnast S, van der Tuin SJ, van der Hoorn JW, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PC, Jukema JW, Princen HM. Kühnast S, et al. Eur Heart J. 2015 Jan 1;36(1):39-48. doi: 10.1093/eurheartj/ehu319. Epub 2014 Aug 20. Eur Heart J. 2015. PMID: 25142968 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information